MedAI newsletter

Archives
Log in
Subscribe
November 13, 2026

MedAI Update: Friday, November 13, 2026

MedAI Update: Daily Digest, Friday, November 13, 2026 AI in medicine policy, explained. Five stories a day, each summarized in plain language.

PART 1: QUICK SUMMARY 1. AMA outlines framework for clinical agentic AI 2. Colorado psychotherapy AI law sets review requirements 3. New documents prompt questions on Medicare AI prior authorization 4. Experts say specialized AI needs subject-matter oversight 5. FDA finalizes Class II status for four devices, including AI tools

PART 2: THE DETAILS

AMA outlines framework for clinical agentic AI Source: https://www.ama-assn.org/practice-management/digital-health/ama-outlines-framework-use-clinical-agentic-ai The American Medical Association says it has outlined a framework for using clinical agentic AI, describing it as part of a push for safety and accountability. The provided text does not include the framework's specific provisions; it also mentions a related report on accountability and responsibility in the AI era. Why it matters: The details are thin, so readers cannot yet see what safeguards or requirements the framework would set.

Colorado psychotherapy AI law sets review requirements Source: https://www.jdsupra.com/legalnews/colorado-joins-other-state-ai-leaders-9643076/ Colorado has enacted three AI-in-health-care laws this year, including HB 26-1195 on AI in psychotherapy services, which took effect Aug. 12. The article says AI may be used for administrative or supplementary support as long as a licensed, registered, or certified individual reviews all AI output, with administrative support including scheduling, billing, and claims processing and supplementary support including therapy records and progress tracking. Why it matters: The text describes permitted uses but does not detail enforcement or penalties, leaving key compliance questions unknown.

New documents prompt questions on Medicare AI prior authorization Source: https://www.statnews.com/2026/11/12/new-documents-raise-more-questions-about-medicares-ai-prior-authorization-experiment/ STAT reports that newly released documents have raised additional questions about Medicare's experiment using AI in prior authorization. The available text is a subscriber preview and does not describe the documents, the questions, or the experiment's design. Why it matters: The available text lacks specifics, so the scope and implications of the experiment are not known from this item.

Experts say specialized AI needs subject-matter oversight Source: https://www.raps.org/resource/experts-specialized-ai-has-great-potential-for-regulatory-needs-sme-oversight.html The RAPS item's headline says experts see strong potential for specialized AI in regulatory work but say it needs subject-matter-expert oversight. The provided text contains only site navigation and no further details about the discussion, examples, or recommendations. Why it matters: Because the text is thin, the basis for the claim and any proposed oversight steps are unknown.

FDA finalizes Class II status for four devices, including AI tools Source: https://insights.citeline.com/medtech-insight/policy-and-regulation/approvals/fda-finalizes-class-ii-status-for-ai-pap-slide-tool-dementia-risk-software-two-vibration-devices-HC5VR7K2NFG4DD3YNVFENPPHVI/ FDA finalized Class II classifications for four devices, including an AI cervical cytology system, mild cognitive impairment prognosis software, and two vibration devices, in orders published Nov. 5 and 6. The article says this lets similar future devices seek clearance through the less rigorous 510(k) pathway. Why it matters: Moving these device types into Class II may change how future products reach market, though the text does not assess safety or performance.

This newsletter is information, not medical advice.

Subscribe to get this digest each morning: https://buttondown.com/vote

Don't miss what's next. Subscribe to MedAI newsletter :
← Newer MedAI Update: Saturday, November 14, 2026 Older → MedAI Update: Thursday, November 12, 2026
Powered by Buttondown, the easiest way to start and grow your newsletter.